InBody continues to work closely with academic researchers on a global scale to develop more in-depth clinical applications of body composition. With our long history in the industry, we provide more than 7,000 research publications. Research title with ★ indicates InBody recommended paper.
Amelioration of fatty liver index in patients with type 2 diabetes on ipragliflozin: an association with glucose-lowering effec
liver disease in the both Western and oriental countries [1, 2]. NAFLD and type 2 diabetes frequently
coex- ist, sharing pathogenetic requisites such as obesity, insulin resistance. Indeed, NAFLD
is highly prevalent (49.6–74%) among patients with type 2 diabetes [3]. Moreover, the presence
of type 2 diabetes is a risk fac- tor not only for the development of nonalcoholic ste- atohepatitis
(NASH), but also for the development of cirrhosis and hepatocellular carcinoma in patients with …
Full text